HUTCHMED (China) HMDCF
NASDAQ HMDCF
$2.16 +0.00 (+0.00%)
At close: Sep 8, 2026 · 4:00 PM EDT

HUTCHMED (China) (HMDCF) Income from Non-Controlling Interests (2015 - 2021)

HUTCHMED (China)'s (HMDCF) quarterly Income from Non-Controlling Interests came in at -$27.6 million in Q4 2021, down 993.73% quarter-over-quarter from $3.1 million in Q3 2021.

Analysis

HUTCHMED (China) (HMDCF) Income from Non-Controlling Interests (2015 - 2021) Analysis & Trends

HUTCHMED (China) (HMDCF) has reported Income from Non-Controlling Interests for 6 consecutive years, with -$27.6 million the latest figure, recorded in Q4 2021.

  • On a quarterly basis, Income from Non-Controlling Interests changed N/A year-over-year to -$27.6 million in Q4 2021; TTM through Dec 2021 was -$27.6 million, a N/A change from a year earlier, with the FY2025 full-year figure at -$823000.0, down 86.62% from the prior year.
  • Income from Non-Controlling Interests was -$27.6 million for Q4 2021 at HUTCHMED (China), down from $3.1 million in the prior quarter.
  • Over five years, Income from Non-Controlling Interests peaked at $3.9 million in Q2 2018 and troughed at -$27.6 million in Q4 2021.
  • A 4-year average of -$2.0 million and a median of -$644500.0 in 2019 frame the typical range for Income from Non-Controlling Interests.
  • Across the five-year window, Income from Non-Controlling Interests surged 158.79% in 2019 and tumbled 191.78% in 2020, its largest moves.
  • Over 4 years, Income from Non-Controlling Interests stood at $788000.0 in 2018, then tumbled by 172.84% to -$574000.0 in 2019, then decreased by 27.7% to -$733000.0 in 2020, then slumped by 3671.21% to -$27.6 million in 2021.
  • The last three Income from Non-Controlling Interests figures came in at -$27.6 million (Q4 2021), $3.1 million (Q3 2021), and -$1.8 million (Q2 2021), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Inc. Minority (Qtr)
1 Amgen 212.35 Bn 198.36 Bn 7.24 Bn -
2 Gilead Sciences 181.19 Bn 178.01 Bn 6.22 Bn -
3 Vertex Pharmaceuticals 132.48 Bn 124.62 Bn 2.84 Bn -
4 Regeneron Pharmaceuticals 82.59 Bn 74.60 Bn 3.93 Bn -
5 Argenx Se 61.45 Bn 56.27 Bn 1.37 Bn -
6 Moderna 54.89 Bn 49.75 Bn 52.00 Mn -
7 Alnylam Pharmaceuticals 34.21 Bn 30.90 Bn 992.69 Mn -
8 Biogen 31.38 Bn 30.10 Bn 1.96 Bn -
9 Roivant Sciences 29.81 Bn 29.81 Bn 1.16 Mn -100.77 Mn
10 HUTCHMED (China) 376.85 Mn 391.04 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2021 -27.64 Mn
Sep 28, 2021 3.09 Mn
Jun 30, 2021 -1.77 Mn
Mar 31, 2021 -1.29 Mn
Jun 30, 2020 -733,000.00
Mar 31, 2020 -715,000.00
Dec 31, 2019 -574,000.00
Sep 30, 2019 143,000.00
Jun 30, 2019 -2.69 Mn
Mar 31, 2019 779,000.00
Dec 31, 2018 788,000.00
Sep 30, 2018 165,000.00
Jun 30, 2018 3.89 Mn
Mar 31, 2018 -1.33 Mn
Jun 30, 2016 -37,000.00
Jun 30, 2015 67,000.00